http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08198820-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5128cfc84a0fb189fceb3cd240c44493 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-19 |
| filingDate | 1995-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60b3e71383ede56b5b87a638cf708e90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4749813b64a8bf9aeba858785ae95233 |
| publicationDate | 1996-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H08198820-A |
| titleOfInvention | Diadamantane derivative and its use |
| abstract | (57) [Summary] [Structure] General formula (1) (In the formula, R represents a hydrogen atom or a lower alkyl group, and n Represents an integer of 0 to 2) or a non-toxic salt thereof and a schizophrenia therapeutic agent containing them as an active ingredient. [Effect] Compound (1) and its non-toxic salt have high affinity for the sigma binding site, but dopamine (D 1 , D 2 ) receptor, serotonin (5-HT 1A , 5-HT 2 ) It has no affinity for neurotransmitter receptors such as receptors. It is also effective as an inhibitory agent for apomorphine-induced climbing, which is used in the evaluation of anti-schizophrenia drugs, and is useful as a therapeutic agent for schizophrenia. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2495020-C1 |
| priorityDate | 1995-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.